The meeting organised by the Regional networks of Central, Eastern Europe, and Central Asia and their global counterparts focused on identifying priorities for the nearest future and sharing best practices.
Following the success of the European Initiative Hepatitis C and Drug Use’s journal supplement “Viral Hepatitis and Drug Use in Europe", the Correlation Network is seeking original research articles on biomedical and public health aspects of HCV and drug use in Europe for publication.
The event raised important points for discussion on the interactions between drug policy, harm reduction and development with a view to the upcoming UNGASS.
The government is examining the proposition to allow drug testing for purity at festivals and clubs as a move towards a harm reduction focused approach to the drug problem.
MAPS Founder speaks with psychedelic research advocates about psychedelic science, MDMA-assisted psychotherapy, and the prospect of making psychedelics legally available for medicinal purposes during a panel discussion at the 2015 International Drug Policy Reform Conference.
Civil society organisations denounce the absence of harm reduction in the first draft of the UNGASS outcome document represents a step backwards from previously agreed language.
VICE discusses the shortfalls of the soon-to-be enacted Psychoactive Substances Bill, including how it could push the drugs market further into obscurity.
The Executive Director of Ghana's NACOB discusses the need for the country to create a legal framework for the provision of opioid substitution therapy.
